Schrödinger, Inc. Joins Shonan Health Innovation Park Membership
Schrödinger joins Shonan iPark to support drug discovery research through its computational platform, aiming to advance and streamline the entire ecosystem.
📋 Article Processing Timeline
- 📰 Published: April 1, 2026 at 20:13
Schrödinger, Inc. (Headquarters: New York, USA, hereinafter "Schrödinger") is pleased to announce its membership in the Shonan Health Innovation Park (hereinafter "Shonan iPark"), a life science ecosystem.
**1. Background and Purpose of Joining**
Schrödinger supports the research and development of pharmaceutical companies and biotech ventures worldwide through the development and provision of a software platform that integrates physics-based simulations and cutting-edge machine learning technologies.
Shonan iPark is one of Japan's largest hubs where pharmaceutical companies, startups, and academia gather to promote open innovation. Through its participation in this community, Schrödinger aims to further develop and streamline the research and development of the entire ecosystem.
**2. Future Activities at Shonan iPark**
With its membership, Schrödinger will contribute to the revitalization of the community through the following activities:
* Holding seminars and workshops: Sharing information on the latest drug discovery workflows and data utilization methods leveraging computational chemistry.
* Strengthening inter-member collaboration: Utilizing Shonan iPark's network to support the exploration of new drug discovery methods through dialogue with companies and organizations with diverse expertise.
**3. Comment**
Comment from Schrödinger, Inc. (Japan subsidiary):
"We are very pleased to become a member of Shonan iPark, a crucial hub for health innovation in Japan. As the digital utilization in drug discovery accelerates, we are committed to ensuring that our platform connects with the diverse researchers at Shonan iPark, thereby contributing to the creation of innovative medicines originating from Japan."
**[About Schrödinger]**
Schrödinger is transforming molecular discovery through its computational platform, which enables the discovery of novel and highly optimized molecules for drug discovery and materials design. Schrödinger's software platform is built upon more than 30 years of research and development investment and is licensed to biotechnology companies, pharmaceutical companies, industrial companies, and academic institutions worldwide. Schrödinger also leverages these platforms to advance a portfolio of collaborative research and internal development programs. For more information, please visit https://www.schrodinger.com.
**1. Background and Purpose of Joining**
Schrödinger supports the research and development of pharmaceutical companies and biotech ventures worldwide through the development and provision of a software platform that integrates physics-based simulations and cutting-edge machine learning technologies.
Shonan iPark is one of Japan's largest hubs where pharmaceutical companies, startups, and academia gather to promote open innovation. Through its participation in this community, Schrödinger aims to further develop and streamline the research and development of the entire ecosystem.
**2. Future Activities at Shonan iPark**
With its membership, Schrödinger will contribute to the revitalization of the community through the following activities:
* Holding seminars and workshops: Sharing information on the latest drug discovery workflows and data utilization methods leveraging computational chemistry.
* Strengthening inter-member collaboration: Utilizing Shonan iPark's network to support the exploration of new drug discovery methods through dialogue with companies and organizations with diverse expertise.
**3. Comment**
Comment from Schrödinger, Inc. (Japan subsidiary):
"We are very pleased to become a member of Shonan iPark, a crucial hub for health innovation in Japan. As the digital utilization in drug discovery accelerates, we are committed to ensuring that our platform connects with the diverse researchers at Shonan iPark, thereby contributing to the creation of innovative medicines originating from Japan."
**[About Schrödinger]**
Schrödinger is transforming molecular discovery through its computational platform, which enables the discovery of novel and highly optimized molecules for drug discovery and materials design. Schrödinger's software platform is built upon more than 30 years of research and development investment and is licensed to biotechnology companies, pharmaceutical companies, industrial companies, and academic institutions worldwide. Schrödinger also leverages these platforms to advance a portfolio of collaborative research and internal development programs. For more information, please visit https://www.schrodinger.com.
FAQ
What is Schrödinger's purpose in joining Shonan iPark?
To support the advancement and efficiency of drug discovery research within the Shonan iPark community through its physics-based computational platform.
What kind of facility is Shonan iPark?
It is one of Japan's largest life science hubs where pharmaceutical companies, startups, and academia gather to promote open innovation.
What specific activities will Schrödinger undertake at Shonan iPark?
Schrödinger plans to hold seminars and workshops on computational chemistry-driven drug discovery workflows and data utilization methods, and strengthen inter-member collaboration.